← Leaderboards
Addanki P Kumar
Amc Cancer Research Center
$4,520,385
Attributed
$4,520,385
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $768.5K · FY2008–20$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$4,520,385 · 6
VA$0 · 2
By mechanism
R01$3,116,492 · 2
R21$1,255,435 · 3
R03$148,458 · 1
I01$0 · 2
Top collaborators
No co-investigators on record.
Most similar at Amc Cancer Research Center
Same institution · by research overlap
- Rita Ghosh$2,790,315
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingTumorCessation Of LifeApoptosisBiochemicalTissuesBaseCancer CellBiologicalPreventSerumIncidenceAnimal ModelResearch StudySignal TransductionInduction Of ApoptosisCancer PatientLaboratoriesGrowthMalignant Neoplasm Of ProstateMolecularInnovationAnimalsCancer Etiology
Grant awards (26)
Therapeutic potential of Palmatine in pancreatic cancer$0
I01 · FY2020 · VA · contact PI
Therapeutic potential of Palmatine in pancreatic cancer$0
I01 · FY2019 · VA · contact PI
Therapeutic potential of Palmatine in pancreatic cancer$0
I01 · FY2018 · VA · contact PI
Therapeutic potential of Palmatine in pancreatic cancer$0
I01 · FY2017 · VA · contact PI
Oxidative stress and programmed death pathways: Cross talk in pancreatic cancer$373,750
R01 · FY2016 · AT · contact PI
Oxidative stress and programmed death pathways: Cross talk in pancreatic cancer$362,537
R01 · FY2015 · AT · contact PI
Oxidative stress and programmed death pathways: Cross talk in pancreatic cancer$362,537
R01 · FY2014 · AT · contact PI
Oxidative stress and programmed death pathways: Cross talk in pancreatic cancer$362,538
R01 · FY2013 · AT · contact PI
Akt/CREB signaling: Target for prostate cancer$0
I01 · FY2013 · VA · contact PI
TARGETING FLIP FOR PROSTATE CANCER PREVENTION$298,893
R01 · FY2012 · CA · contact PI
Oxidative stress and programmed death pathways: Cross talk in pancreatic cancer$138,212
R01 · FY2012 · AT · contact PI
Akt/CREB signaling: Target for prostate cancer$0
I01 · FY2012 · VA · contact PI
TARGETING FLIP FOR PROSTATE CANCER PREVENTION$298,893
R01 · FY2011 · CA · contact PI
Nexrutine Phellodendron amurense bark extract: Potential use in Pancreatic Cancer$183,769
R21 · FY2011 · AT · contact PI
Akt/CREB signaling: Target for prostate cancer$0
I01 · FY2011 · VA · contact PI
TARGETING FLIP FOR PROSTATE CANCER PREVENTION$308,138
R01 · FY2010 · CA · contact PI
Nexrutine Phellodendron amurense bark extract: Potential use in Pancreatic Cancer$222,750
R21 · FY2010 · AT · contact PI
SIRT1 as a Resveratrol target in PTEN knockout Prostate Cancer Model$163,350
R21 · FY2010 · CA · contact PI
Eugenol & 2-methoxyestradiol: combination approach to prostate cancer prevention$74,250
R03 · FY2010 · CA · contact PI
TARGETING FLIP FOR PROSTATE CANCER PREVENTION$307,878
R01 · FY2009 · CA · contact PI
SIRT1 as a Resveratrol target in PTEN knockout Prostate Cancer Model$187,246
R21 · FY2009 · CA · contact PI
Eugenol & 2-methoxyestradiol: combination approach to prostate cancer prevention$74,208
R03 · FY2009 · CA · contact PI
TARGETING FLIP FOR PROSTATE CANCER PREVENTION$303,116
R01 · FY2008 · CA · contact PI
Nexrutine, a herbal extract and prostate cancer$144,009
R21 · FY2004 · CA
Nexrutine, a herbal extract and prostate cancer$105,151
R21 · FY2004 · CA
Nexrutine, a herbal extract and prostate cancer$249,160
R21 · FY2003 · CA